在利福昔明治疗期间体内筛选利福霉素耐药艰难梭菌。
In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
机构信息
TechLab, Inc., Blacksburg, Virginia, USA.
出版信息
Antimicrob Agents Chemother. 2012 Nov;56(11):6019-20. doi: 10.1128/AAC.00974-12. Epub 2012 Aug 20.
Abstract
We report the selection of Clostridium difficile resistant to the rifamycin class of antibiotics in a patient within 32 h of receiving rifaximin for the treatment of recurrent C. difficile diarrhea. Resistance was associated with single nucleotide substitutions within rpoB.
摘要
我们报道了一名患者在接受利福昔明治疗复发性艰难梭菌腹泻后 32 小时内对利福霉素类抗生素耐药的艰难梭菌的选择。耐药性与 rpoB 内的单核苷酸取代有关。
相似文献
1
In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
Antimicrob Agents Chemother. 2012 Nov;56(11):6019-20. doi: 10.1128/AAC.00974-12. Epub 2012 Aug 20.
2
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7. doi: 10.1128/AAC.00342-08. Epub 2008 Jun 16.
3
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.
Antimicrob Agents Chemother. 2013 Jun;57(6):2690-3. doi: 10.1128/AAC.00548-13. Epub 2013 Apr 1.
4
Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5604-7. doi: 10.1128/AAC.01137-16. Print 2016 Sep.
5
Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.
J Clin Microbiol. 2011 Dec;49(12):4319-21. doi: 10.1128/JCM.05100-11. Epub 2011 Oct 12.
6
In vivo selection of moxifloxacin-resistant Clostridium difficile.
Antimicrob Agents Chemother. 2012 May;56(5):2788-9. doi: 10.1128/AAC.06433-11. Epub 2012 Feb 27.
7
High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.
Clin Infect Dis. 2009 Feb 15;48(4):425-9. doi: 10.1086/596315.
8
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.
Ann Pharmacother. 2008 Jun;42(6):827-35. doi: 10.1345/aph.1K675. Epub 2008 Apr 22.
9
Fluoroquinolone resistance and Clostridium difficile, Germany.
Emerg Infect Dis. 2010 Apr;16(4):675-7. doi: 10.3201/eid1604.090859.
10
In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
Antimicrob Agents Chemother. 2011 Mar;55(3):992-6. doi: 10.1128/AAC.00688-10. Epub 2010 Dec 13.
引用本文的文献
1
Infection: Diagnosis and Treatment Challenges.
Pathogens. 2024 Jan 27;13(2):118. doi: 10.3390/pathogens13020118.
2
Antibiotic Resistances of Clostridioides difficile.
Adv Exp Med Biol. 2024;1435:169-198. doi: 10.1007/978-3-031-42108-2_9.
3
Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.
Curr Opin Microbiol. 2022 Apr;66:63-72. doi: 10.1016/j.mib.2022.01.004. Epub 2022 Jan 22.
4
Antimicrobial resistance in Clostridioides difficile.
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2459-2478. doi: 10.1007/s10096-021-04311-5. Epub 2021 Aug 24.
5
Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile.
J Antimicrob Chemother. 2021 Mar 12;76(4):967-972. doi: 10.1093/jac/dkaa522.
6
Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015.
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00296-20.
7
Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).
Rev Esp Quimioter. 2020 Apr;33(2):151-175. doi: 10.37201/req/2065.2020. Epub 2020 Feb 20.
8
An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1777-1786. doi: 10.1007/s10096-017-2991-y. Epub 2017 May 13.
9
Conventional and alternative treatment approaches for infection.
Int J Health Sci (Qassim). 2017 Jan-Mar;11(1):1-10.
10
Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.
J Neurogastroenterol Motil. 2017 Jan 30;23(1):9-19. doi: 10.5056/jnm16124.
本文引用的文献
1
In vivo selection of moxifloxacin-resistant Clostridium difficile.
Antimicrob Agents Chemother. 2012 May;56(5):2788-9. doi: 10.1128/AAC.06433-11. Epub 2012 Feb 27.
2
Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.
J Clin Microbiol. 2011 Dec;49(12):4319-21. doi: 10.1128/JCM.05100-11. Epub 2011 Oct 12.
3
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.
J Antimicrob Chemother. 2011 Dec;66(12):2850-5. doi: 10.1093/jac/dkr377. Epub 2011 Sep 21.
4
Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.
Anaerobe. 2009 Dec;15(6):290-1. doi: 10.1016/j.anaerobe.2009.08.004. Epub 2009 Aug 18.
5
High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.
Clin Infect Dis. 2009 Feb 15;48(4):425-9. doi: 10.1086/596315.
6
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7. doi: 10.1128/AAC.00342-08. Epub 2008 Jun 16.
7
Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile.
J Clin Microbiol. 2004 Dec;42(12):5710-4. doi: 10.1128/JCM.42.12.5710-5714.2004.
8
PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes.
J Clin Microbiol. 1999 Feb;37(2):461-3. doi: 10.1128/JCM.37.2.461-463.1999.
9
Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus.
Antimicrob Agents Chemother. 1998 Oct;42(10):2590-4. doi: 10.1128/AAC.42.10.2590.
Zotero 插件